DelveInsight’s “Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Follicular Lymphoma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Follicular Lymphoma drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Follicular Lymphoma treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Follicular Lymphoma: An Overview
As per the Leukemia & Lymphoma Society, Non-Hodgkin Lymphoma (NHL) is a type of cancer that generally develops in the lymph nodes and lymphatic tissue found in organs such as the stomach, intestines, or skin. In some cases, the NHL involves bone marrow and blood.
NHL is classified based on the type of lymphocyte involved: B lymphocytes (B cells), T lymphocytes (T-cells), and Natural killer cells. NHL can also be indolent (slow progression) or aggressive (rapid progression).
According to the Lymphoma Research Foundation, Follicular Lymphoma (FL) is a slow-growing or indolent form of non-Hodgkin lymphoma (NHL) that arises from B-lymphocytes. This lymphoma subtype accounts for 20–30% of all NHL cases. FL is usually a slow-growing (indolent) lymphoma, although some FL can grow rapidly.
Often patients at the time of diagnosis have obvious symptoms of the disease. The common symptoms of FL include enlargement of the lymph nodes in the neck, underarms, abdomen, or groin, as well as fatigue, shortness of breath, night sweats, and weight loss. If FL occurs in the bone marrow, it leads to anemia, thrombocytopenia, and neutropenia.
Follicular Lymphoma Market Key Facts
-
As per the SEER database, the incidence of FL in the US is 2.6/100,000 men and per year based on 2015–2019 cases, age-adjusted. Stage I of FL accounted for 25% of total cases, stage II 15%, stage III 26%, stage IV 27%, and unknown 7%.
-
According to a study by Liu W. et al (2021), demonstrated that 10–20% of patients who are treated with immunochemotherapy experience relapse within 24 months of diagnosis, and these patients have a significantly worse outcome compared to those who do not. The distribution of low, intermediate, and high-risk was 36%, 37%, and 27%, respectively.
-
According to a study by Kanas et. al (2021), the incidence Cases of FL are approximately 3,300, 2,900, 2,800, 1,700, and 2,800 in Germany, France, Italy, Spain, and the UK respectively.
-
According to a study by the Center for International Blood and Marrow Transplant Research estimates that among patients with follicular lymphoma who are potential transplant candidates, fewer than 5% actually undergo transplantation. This accounts for about 150 to 200 auto-transplants a year in the US.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Follicular Lymphoma pipeline therapies. It also thoroughly assesses the Follicular Lymphoma market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Follicular Lymphoma drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Follicular Lymphoma Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Follicular Lymphoma epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Follicular Lymphoma epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Follicular Lymphoma Epidemiology, Segmented as –
-
Total Follicular Lymphoma Incident Cases
-
Follicular Lymphoma Risk-specific Incident Cases
-
Follicular Lymphoma Stage-specific Incident Cases
-
Follicular Lymphoma Mutation-specific Incident Cases
-
Follicular Lymphoma Refractory/Relapsed Incident Cases
-
Follicular Lymphoma Treatable Cases
Follicular Lymphoma Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Follicular Lymphoma market or expected to be launched during the study period. The analysis covers the Follicular Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Follicular Lymphoma drugs based on their sale and market share.
The report also covers the Follicular Lymphoma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Follicular Lymphoma companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Follicular Lymphoma Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/follicular-lymphoma-market-insights
Follicular Lymphoma Therapeutics Analysis
There are various treatment options for FL based on the severity of associated symptoms and the rate of cancer growth. If patients show no or very few symptoms, physicians recommend not to treat the disease right away—an approach referred to as active surveillance (“watch and wait”).
The treatment of FL includes CAR T cell therapies, chemotherapy, radiation therapy, immunotherapy, and stem cell transplant. Patients with early-stage FL (Ann Arbor stages I or II) may be treated with radiation therapy alone or with radiation plus chemotherapy.
Patients with advanced disease are usually treated first with chemotherapy plus anti-CD20 antibodies sometimes called chemoimmunotherapy. The most common antibodies used are rituximab (Rituxan) and obinutuzumab (Gazyva), which selectively target follicular lymphoma tumor cells. Older people without organ dysfunction can be treated with rituximab only.
CAR T-cell therapies are playing an important role in the treatment of Follicular Lymphoma. in May 2022, Novartis announced that the European Commission (EC) has approved Kymriah (tisagenlecleucel) for the treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy.
Follicular Lymphoma Companies Actively Working in the Therapeutics Market Include
-
Incyte Corporation
-
Genmab A/S
-
BeiGene
-
Merck & Co.
-
ADC Therapeutics
-
Xynomic Pharmaceuticals
-
Nordic Nanovector
-
TG Therapeutics Inc
-
Allogene Therapeutics
-
MEI Pharma
-
Innovent Biologics
And Many More
Emerging and Marketed Follicular Lymphoma Therapies Covered in the Report Include:
-
Tafasitamab: Incyte Corporation
-
Epcoritamab: Genmab A/S
-
Zanubrutinib – BeiGene
-
Pembrolizumab: Merck & Co.
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/follicular-lymphoma-market-insights
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Follicular Lymphoma Competitive Intelligence Analysis
4. Follicular Lymphoma Market Overview at a Glance
5. Follicular Lymphoma Disease Background and Overview
6. Follicular Lymphoma Patient Journey
7. Follicular Lymphoma Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Follicular Lymphoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Follicular Lymphoma Unmet Needs
10. Key Endpoints of Follicular Lymphoma Treatment
11. Follicular Lymphoma Marketed Therapies
12. Follicular Lymphoma Emerging Drugs and Latest Therapeutic Advances
13. Follicular Lymphoma Seven Major Market Analysis
14. Attribute Analysis
15. Follicular Lymphoma Market Outlook (In US, EU5, and Japan)
16. Follicular Lymphoma Companies Active in the Market
17. Follicular Lymphoma Access and Reimbursement Overview
18. KOL Views on the Follicular Lymphoma Market
19. Follicular Lymphoma Market Drivers
20. Follicular Lymphoma Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/follicular-lymphoma-market-insights
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Cushing’s Syndrome Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Cushing’s Syndrome market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Cushing’s Syndrome market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices